Literature DB >> 26293837

Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis.

Michael N Mavros1,2,3, Li Xu2,4,5, Hadia Maqsood2, Faiz Gani2, Aslam Ejaz6, Gaya Spolverato2, Waddah B Al-Refaie7, Steven M Frank8, Timothy M Pawlik9.   

Abstract

BACKGROUND: Perioperative blood transfusion (PBT) is common in pancreatic surgery. Recent studies have suggested that PBT may be associated with worse long-term outcomes.
METHODS: A systematic review and meta-analysis of studies comparing long-term clinical outcomes of cancer patients undergoing curative-intent pancreatic surgery with regard to occurrence of PBT was performed.
RESULTS: A total of 23 studies (4339 patients) were included in the systematic review, and 19 studies (3646 patients) were included in the meta-analysis. Nearly half (45.8 %) of all patients were female (range 25-60 %), and median age ranged from 59 to 72 years. About half (46.5 %, range 19-72 %) of the patients were transfused. Most had pancreatic ductal adenocarcinoma (69.5 %), while others had ampullary carcinoma (15.0 %), cholangiocarcinoma (7.4 %), or exocrine tumors of pancreas (8.1 %). Most (91.1 %) underwent pancreaticoduodenectomy, while the remaining patients underwent a total or distal pancreatectomy. The 5-year overall survival for all patients ranged from 0 to 65 %. Thirteen and nine of 19 studies reported a detrimental effect of PBT on survival on univariable and multivariable analysis, respectively. Overall, PBT was associated with shorter overall survival (pooled odds ratio 2.43, 95 % confidence interval 1.90-3.10); this finding was reproduced in sensitivity analysis.
CONCLUSIONS: Patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery. Further research should focus on implementing guidelines for and discerning factors associated with the poor outcomes after PBT.

Entities:  

Mesh:

Year:  2015        PMID: 26293837     DOI: 10.1245/s10434-015-4823-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection.

Authors:  Fabio Bagante; Gaya Spolverato; Andrea Ruzzenente; Ana Wilson; Faiz Gani; Simone Conci; Alexander Yahanda; Tommaso Campagnaro; Alfredo Guglielmi; Timothy M Pawlik
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

2.  Declining Use of Red Blood Cell Transfusions for Gastrointestinal Cancer Surgery: A Population-Based Analysis.

Authors:  Jesse Zuckerman; Natalie Coburn; Jeannie Callum; Alyson L Mahar; Victoria Zuk; Yulia Lin; Robin McLeod; Alexis F Turgeon; Haoyu Zhao; Emily Pearsall; Guillaume Martel; Julie Hallet
Journal:  Ann Surg Oncol       Date:  2020-11-09       Impact factor: 5.344

Review 3.  Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival.

Authors:  Marianne Sinn; Marcus Bahra; Timm Denecke; Sue Travis; Uwe Pelzer; Hanno Riess
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

4.  Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Authors:  Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee
Journal:  J Gastrointest Surg       Date:  2016-10-24       Impact factor: 3.452

5.  Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.

Authors:  Akshat Saxena; Sarah J Valle; Winston Liauw; David L Morris
Journal:  J Gastrointest Surg       Date:  2017-05-30       Impact factor: 3.452

6.  Impact of Delta Hemoglobin on Provider Transfusion Practices and Post-operative Morbidity Among Patients Undergoing Liver and Pancreatic Surgery.

Authors:  Gaya Spolverato; Fabio Bagante; Matthew Weiss; Jin He; Christopher L Wolfgang; Fabian Johnston; Martin A Makary; Will Yang; Steven M Frank; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-09-30       Impact factor: 3.452

7.  Improvement of the Surgical Apgar Score by Addition of Intraoperative Blood Transfusion Among Patients Undergoing Major Gastrointestinal Surgery.

Authors:  Aslam Ejaz; Faiz Gani; Steven M Frank; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-08-12       Impact factor: 3.452

8.  Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study.

Authors:  Haisu Dai; Haowei Chen; Wei Liu; Yu You; Jiaxin Tan; Aigang Yang; Xiangdong Lai; Ping Bie
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-21       Impact factor: 4.553

9.  Perioperative Glucocorticoids are Associated with Improved Recurrence-Free Survival After Pancreatic Cancer Surgery: A Retrospective Cohort Study with Propensity Score-Matching.

Authors:  Yun-Xiao Zhang; Dong-Liang Mu; Ke-Min Jin; Xue-Ying Li; Dong-Xin Wang
Journal:  Ther Clin Risk Manag       Date:  2021-01-22       Impact factor: 2.423

10.  The Effect of Perioperative Blood Transfusion on Long-Term Survival Outcomes After Surgery for Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Authors:  Linda Ye; Edward H Livingston; Bethany Myers; O Joe Hines
Journal:  Pancreas       Date:  2021 May-Jun 01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.